<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34107252</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Human amyotrophic lateral sclerosis excitability phenotype screen: Target discovery and validation.</ArticleTitle><Pagination><StartPage>109224</StartPage><MedlinePgn>109224</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.109224</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)00575-1</ELocationID><Abstract><AbstractText>Drug development is hampered by poor target selection. Phenotypic screens using neurons differentiated from patient stem cells offer the possibility to validate known and discover novel disease targets in an unbiased fashion. To identify targets for managing hyperexcitability, a pathological feature of amyotrophic lateral sclerosis (ALS), we design a multi-step screening funnel using patient-derived motor neurons. High-content live cell imaging is used to evaluate neuronal excitability, and from a screen against a chemogenomic library of 2,899 target-annotated compounds, 67 reduce the hyperexcitability of ALS motor neurons carrying the SOD1(A4V) mutation, without cytotoxicity. Bioinformatic deconvolution identifies 13 targets that modulate motor neuron excitability, including two known ALS excitability modulators, AMPA receptors and Kv7.2/3 ion channels, constituting target validation. We also identify D2 dopamine receptors as modulators of ALS motor neuron excitability. This screen demonstrates the power of human disease cell-based phenotypic screens for identifying clinically relevant targets for neurological disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roet</LastName><ForeName>Kasper C D</ForeName><Initials>KCD</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medicine Design, Pfizer, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brault</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medicine Design, Pfizer, Groton, CT 06340, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Allison P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Rare Disease Research Unit, Pfizer, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jefferson</LastName><ForeName>Anne B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Pfizer Centers for Therapeutic Innovation (CTI), San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klug-McLeod</LastName><ForeName>Jackie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medicine Design, Pfizer, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leach</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Pfizer Centers for Therapeutic Innovation (CTI), Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Fabien</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medicine Design, Pfizer, Groton, CT 06340, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hongying</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pfizer Centers for Therapeutic Innovation (CTI), Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coyle</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Pfizer Centers for Therapeutic Innovation (CTI), Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Lyn H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Medicine Design, Pfizer, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Devlin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiskow</LastName><ForeName>Ole</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Department of Molecular and Cellular Biology, Harvard Stem Cell Institute, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kuchuan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Rie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grantham</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dornon</LastName><ForeName>Mary K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klim</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Department of Molecular and Cellular Biology, Harvard Stem Cell Institute, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siekmann</LastName><ForeName>Marco T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Dongyi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seungkyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Department of Molecular and Cellular Biology, Harvard Stem Cell Institute, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolf</LastName><ForeName>Clifford J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. Electronic address: clifford.woolf@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS105076</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD090255</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">AMPA toxicity</Keyword><Keyword MajorTopicYN="N">D2 receptor</Keyword><Keyword MajorTopicYN="N">Kv7</Keyword><Keyword MajorTopicYN="N">high content</Keyword><Keyword MajorTopicYN="N">high throughput</Keyword><Keyword MajorTopicYN="N">hyperexcitability</Keyword><Keyword MajorTopicYN="N">phenotypic screen</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare the following competing financial interests: K.C.D.R., K.E., and C.J.W. are founders of QurAlis; L.Z., A.B., A.P.B., A.B.J., J.K.M., K.L.L., F.V., H.Y., L.H.J., and A.J.C. are current or previous employees of Pfizer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>9</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34107252</ArticleId><ArticleId IdType="mid">NIHMS1713045</ArticleId><ArticleId IdType="pmc">PMC8209673</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109224</ArticleId><ArticleId IdType="pii">S2211-1247(21)00575-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akamatsu M, Yamashita T, Hirose N, Teramoto S, and Kwak S (2016). The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci. Rep 6, 28649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923865</ArticleId><ArticleId IdType="pubmed">27350567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ba&#x31c;czyk M, Alami NO, Delestr&#xe9;e N, Martinot C, Tang L, Commisso B, Bayer D, Doisne N, Frankel W, Manuel M, et al. (2020). Synaptic restoration by cAMP/PKA drives activity-dependent neuroprotection to motoneurons in ALS. J. Exp. Med 217, e20191734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7398175</ArticleId><ArticleId IdType="pubmed">32484501</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu JM, and Gainetdinov RR (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev 63, 182&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">21303898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M, Phatnani HP, Puddifoot CA, Story D, Fletcher J, et al. (2012). Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. USA 109, 5803&#x2013;5808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326463</ArticleId><ArticleId IdType="pubmed">22451909</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzi Y, and Borrelli E (2006). Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? Trends Neurosci. 29, 167&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443286</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Bartolom&#xe9;-Mart&#xed;n D, Rotem N, Rozas C, Dellal SS, Chacon MA, Kadriu B, Gulinello M, Khodakhah K, and Faber DS (2015). Rescue of homeostatic regulation of striatal excitability and locomotor activity in a mouse model of Huntington&#x2019;s disease. Proc. Natl. Acad. Sci. USA 112, 2239&#x2013;2244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4343133</ArticleId><ArticleId IdType="pubmed">25646456</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Cichon J, Wang W, Qiu L, Lee SJ, Campbell NR, Destefino N, Goard MJ, Fu Z, Yasuda R, et al. (2012). Imaging neural activity using Thy1-GCaMP transgenic mice. Neuron 76, 297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4059513</ArticleId><ArticleId IdType="pubmed">23083733</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TW, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A, Schreiter ER, Kerr RA, Orger MB, Jayaraman V, et al. (2013). Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature 499, 295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777791</ArticleId><ArticleId IdType="pubmed">23868258</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong F, Cheung AK, and Huang SM (2012). Chemical genetics-based target identification in drug discovery. Annu. Rev. Pharmacol. Toxicol 52, 57&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">21819237</ArticleId></ArticleIdList></Reference><Reference><Citation>Delestr&#xe9;e N, Manuel M, Iglesias C, Elbasiouny SM, Heckman CJ, and Zytnicki D (2014). Adult spinal motoneurones are not hyperexcitable in a mouse model of inherited amyotrophic lateral sclerosis. J. Physiol 592, 1687&#x2013;1703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979619</ArticleId><ArticleId IdType="pubmed">24445319</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Erchia AM, Gallo A, Manzari C, Raho S, Horner DS, Chiara M, Val-letti A, Aiello I, Mastropasqua F, Ciaccia L, et al. (2017). Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci. Rep 7, 10046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5577269</ArticleId><ArticleId IdType="pubmed">28855684</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin AC, Burr K, Borooah S, Foster JD, Cleary EM, Geti I, Vallier L, Shaw CE, Chandran S, and Miles GB (2015). Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat. Commun 6, 5999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338554</ArticleId><ArticleId IdType="pubmed">25580746</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Boulting GL, Bobrowicz S, and Eggan KC (2008). Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 3, 637&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041780</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong W, Ma Y, Guan F, Zhang X, Chen W, Zhang L, and Zhang L (2021). Ablation of C9orf72 together with excitotoxicity induces ALS in rats. FEBS J. 288, 1712&#x2013;1723.</Citation><ArticleIdList><ArticleId IdType="pubmed">32745320</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, et al. (2013). RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, Hadano S, Aoki M, Saya H, Sobue G, and Okano H (2018). Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med 24, 1579&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P,&#xd6;zdinler PH, Kiernan MC, and Vucic S (2016). Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat. Rev. Neurol 12, 651&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">27658852</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene DL, and Hoshi N (2017). Modulation of Kv7 channels and excitability in the brain. Cell. Mol. Life Sci 74, 495&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5243414</ArticleId><ArticleId IdType="pubmed">27645822</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, Hotta A, Kondo T, Kitaoka S, Ohta A, et al. (2017). The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med 9, eaaf3962.</Citation><ArticleIdList><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai Y, Shibuya K, Misawa S, Sekiguchi Y, Watanabe K, Amino H, and Kuwabara S (2016). Axonal Dysfunction Precedes Motor Neuronal Death in Amyotrophic Lateral Sclerosis. PLoS ONE 11, e0158596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934877</ArticleId><ArticleId IdType="pubmed">27383069</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen DB, Kadlecova M, Allodi I, and Meehan CF (2020). Spinal motoneurones are intrinsically more responsive in the adult G93A SOD1 mouse model of amyotrophic lateral sclerosis. J. Physiol 598, 4385&#x2013;4403.</Citation><ArticleIdList><ArticleId IdType="pubmed">32716521</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin LJ, Schlesinger F, Song YP, Dengler R, and Krampfl K (2010). The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: a patch-clamp study. Pharmacology 85, 54&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20051697</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones LH, and Bunnage ME (2017). Applications of chemogenomic library screening in drug discovery. Nat. Rev. Drug Discov 16, 285&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">28104905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Shibuya K, Sato Y, Misawa S, Nasu S, Sekiguchi Y, Mitsuma S, Isose S, Fujimaki Y, Ohmori S, et al. (2012). Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 83, 734&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">22566594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning KC, Kaplan A, and Henderson CE (2010). Motor neuron diversity in development and disease. Annu. Rev. Neurosci 33, 409&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Khademullah CS, Aqrabawi AJ, Place KM, Dargaei Z, Liang X, Pressey JC, Bedard S, Yang JW, Garand D, Keramidis I, et al. (2020). Cortical interneuron-mediated inhibition delays the onset of amyotrophic lateral sclerosis. Brain 143, 800&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">32203578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Kanki R, Yamashita H, and Akaike A (2002). Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J. Neurosci. Res 70, 274&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Hughes EG, Shetty AS, Arlotta P, Goff LA, Bergles DE, and Brown SP (2017). Changes in the Excitability of Neocortical Neurons in a Mouse Model of Amyotrophic Lateral Sclerosis Are Not Specific to Corticospinal Neurons and Are Modulated by Advancing Disease. J. Neurosci 37, 9037&#x2013;9053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5597984</ArticleId><ArticleId IdType="pubmed">28821643</ArticleId></ArticleIdList></Reference><Reference><Citation>King AE, Woodhouse A, Kirkcaldie MT, and Vickers JC (2016). Excitotoxicity in ALS: Overstimulation, or overreaction? Exp. Neurol 275, 162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">26584004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E, Sandoe J, Williams LA, Boulting GL, Moccia R, Wainger BJ, Han S, Peng T, Thams S, Mikkilineni S, et al. (2014). Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 14, 781&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, et al. (2019). ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci 22, 167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalchuk MO, Heuberger JAAC, Sleutjes BTHM, Ziagkos D, van den Berg LH, Ferguson TA, Franssen H, and Groeneveld GJ (2018). Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Clin. Pharmacol. Ther 104, 1136&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">29672831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo JJ, Siddique T, Fu R, and Heckman CJ (2005). Increased persistent Na(+) current and its effect on excitability in motoneurones cultured from mutant SOD1 mice. J. Physiol 563, 843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1665614</ArticleId><ArticleId IdType="pubmed">15649979</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy F, Lamotte d&#x2019;Incamps B, Imhoff-Manuel RD, and Zytnicki D (2014). Early intrinsic hyperexcitability does not contribute to motoneuron degeneration in amyotrophic lateral sclerosis. eLife 3, 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4227046</ArticleId><ArticleId IdType="pubmed">25313866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, Lu Y, Gendron TF, Karydas A, Tran H, Yang D, Pet-rucelli L, Miller BL, Almeida S, and Gao FB (2016). Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron 92, 383&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Silva ML, Imhoff-Manuel RD, Sharma A, Heckman CJ, Shneider NA, Roselli F, Zytnicki D, and Manuel M (2018). Hypoexcitability precedes denervation in the large fast-contracting motor units in two unrelated mouse models of ALS. eLife 7, e04046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5922970</ArticleId><ArticleId IdType="pubmed">29580378</ArticleId></ArticleIdList></Reference><Reference><Citation>McCall RB, Lookingland KJ, B&#xe9;dard PJ, and Huff RM (2005). Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson&#x2019;s disease. J. Pharmacol. Exp. Ther 314, 1248&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980060</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata E, Ogino M, Iwamoto K, Kitagawa Y, Iwasaki Y, Yoshii F, Ikeda JE, and Investigators ALSC; ALS Consortium Investigators (2016). Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients. PLoS ONE 11, e0149509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765990</ArticleId><ArticleId IdType="pubmed">26910108</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakata M, Kuwabara S, Kanai K, Misawa S, Tamura N, Sawai S, Hat-tori T, and Bostock H (2006). Distal excitability changes in motor axons in amyotrophic lateral sclerosis. Clin. Neurophysiol 117, 1444&#x2013;1448.</Citation><ArticleIdList><ArticleId IdType="pubmed">16765084</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SB, Kiernan MC, and Vucic S (2017). Axonal Excitability in Amyotrophic Lateral Sclerosis : Axonal Excitability in ALS. Neurotherapeutics 14, 78&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233634</ArticleId><ArticleId IdType="pubmed">27878516</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M, Albo F, Gaetti C, Spalloni A, Bengtson CP, Longone P, Caval-canti S, and Zona C (2003). Altered excitability of motor neurons in a transgenic mouse model of familial amyotrophic lateral sclerosis. Neurosci. Lett 351, 153&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">14623129</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W, and Philips T (2013). The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci 14, 248&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, and Sabatini DM (2008). The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2475333</ArticleId><ArticleId IdType="pubmed">18497260</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Kimura J, and Shimohama S (1998). Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol 44, 110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">9667598</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Roselli F, Singh K, Leptien K, Julien JP, Gros-Louis F, and Caroni P (2013). Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron 80, 80&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24094105</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj BT, Livesey MR, Zhao C, Gregory JM, James OT, Cleary EM, Chouhan AK, Gane AB, Perkins EM, Dando O, et al. (2018). C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity. Nat. Commun 9, 347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman SP, and Bang AG (2018). High-throughput screen for compounds that modulate neurite growth of human induced pluripotent stem cell-derived neurons. Dis. Model. Mech 11, dmm031906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5894944</ArticleId><ArticleId IdType="pubmed">29361516</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, Li Y, Chang WH, Hung ST, Hendricks E, Li-nares GR, Wang Y, Son EY, et al. (2018). Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med 24, 313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Park SB, Geevasinga N, Menon P, Howells J, Simon NG, Huynh W, Noto Y, G&#xf6;tz J, Kril JJ, et al. (2016). Motor cortical function determines prognosis in sporadic ALS. Neurology 87, 513&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">27402895</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;i&#x161;kov&#xe1; Z, Justus D, Kaneko H, Friedrichs D, Henneberg N, Beutel T, Pitsch J, Schoch S, Becker A, von der Kammer H, and Remy S (2014). Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer&#x2019;s disease. Neuron 84, 1023&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">25456500</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacey P, Wassermann AM, Kammonen L, Impey E, Wilbrey A, and Cawkill D (2018). Plate-Based Phenotypic Screening for Pain Using Human iPSC-Derived Sensory Neurons. SLAS Discov. 23, 585&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">29547351</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert B, Peuscher MH, Hynynen M, Chen A, Neve RL, Brown RH Jr., Constantine-Paton M, and Bellingham MC (2008). Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J. Neurosci 28, 10864&#x2013;10874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844745</ArticleId><ArticleId IdType="pubmed">18945894</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent F, Loria P, Pregel M, Stanton R, Kitching L, Nocka K, Doyon-nas R, Steppan C, Gilbert A, Schroeter T, and Peakman MC (2015). Developing predictive assays: the phenotypic screening &#x201c;rule of 3&#x201d;. Sci. Transl. Med 7, 293ps15.</Citation><ArticleIdList><ArticleId IdType="pubmed">26109101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, Perez NP, Williams LA, Lee S, Boulting G, et al. (2014). Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 7, 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maraga-kis NJ, Bedlack R, Goyal NA, Rutkove SB, Lange DJ, et al. (2021). Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 78, 186&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Ji X, Liu J, Li Z, and Zhang X (2018). Dopamine Receptor Subtypes Differentially Regulate Autophagy. Int. J. Mol. Sci 19, 1540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983733</ArticleId><ArticleId IdType="pubmed">29786666</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss JH (2011). Ca permeable AMPA channels in diseases of the nervous system. Front. Mol. Neurosci 4, 42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3214733</ArticleId><ArticleId IdType="pubmed">22102834</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, Tank EM, Miguez R, McBride JP, G&#xf3;mez NB, White M, Lin Z, Gonzalez CM, Serio A, Sreedharan J, and Barmada SJ (2020). Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. J. Clin. Invest 130, 1139&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269575</ArticleId><ArticleId IdType="pubmed">31714900</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YM, Gupta SK, Kim KJ, Powers BE, Cerqueira A, Wainger BJ, Ngo HD, Rosowski KA, Schein PA, Ackeifi CA, et al. (2013). A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12, 713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707511</ArticleId><ArticleId IdType="pubmed">23602540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>